Volume | 5,074 |
|
|||||
News | - | ||||||
Day High | 1.495 | Low High |
|||||
Day Low | 1.4601 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Cocrystal Pharma Inc | COCP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.47 | 1.4601 | 1.495 | 1.495 | 1.43 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
48 | 5,074 | $ 1.47 | $ 7,465 | - | 1.325 - 3.285 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:06:19 | 8 | $ 1.47 | USD |
Cocrystal Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
15.16M | 10.17M | - | 2.6M | -17.98M | -1.77 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cocrystal Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical COCP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.58 | 1.58 | 1.35 | 1.45 | 14,163 | -0.085 | -5.38% |
1 Month | 1.50 | 1.74 | 1.35 | 1.48 | 19,260 | -0.005 | -0.33% |
3 Months | 1.63 | 1.74 | 1.325 | 1.50 | 14,216 | -0.135 | -8.28% |
6 Months | 1.81 | 1.99 | 1.325 | 1.63 | 16,724 | -0.315 | -17.40% |
1 Year | 2.47 | 3.285 | 1.325 | 2.21 | 23,777 | -0.975 | -39.47% |
3 Years | 14.40 | 41.52 | 1.325 | 19.15 | 1,834,720 | -12.91 | -89.62% |
5 Years | 31.20 | 49.20 | 1.325 | 18.86 | 2,050,919 | -29.71 | -95.21% |
Cocrystal Pharma Description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). |